From: Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases
 | Mouse TrB cell | Human TrB cell |
---|---|---|
Phenotypes | T1: CD24hiCD21loCD23loIgMhiIgDlo T2: CD24hiCD21hiCD23hiIgMhiIgDhi | T1: CD19+CD24hiCD21loCD23loIgMhiIgDlo T2: CD19+CD24hiCD21hiCD23hiIgMhiIgDhi |
T1: CD24+++CD21−CD23−IgM+++IgD−CD93+CD62L− T2: CD24+++CD21++CD23++IgM+++IgD++CD93+CD62L− T3: D24+++CD21++CD23++IgM++IgD++CD93+CD62L+ | T1: R123+CD38+++CD24+++CD10+IgD+CD27− T2: R123+CD38++CD24++CD10+IgD+CD27− T3: R123+CD38+CD24+CD10+IgD+CD27− | |
T1: CD19+CD24hiCD38hiCD27IgMhiIgDloCD10hiCD21loCD32hi T2: CD19+CD24hiCD38hiCD27IgMinIgDinCD10inCD21loCD32in T3: CD19+CD24hiCD38hiCD27IgMloIgDloCD10loCD21loCD32lo CD27+TrB: CD19+CD24hiCD38hiCD27+ | ||
Locations | BM, PB, Spleen | BM, PB, CB and secondary lymphoid tissues (spleen, tonsil, lymph node and GALT) |
The proportion of B cells | BM: 15–20% | BM: 6.3% |
PB: 15–20% | PB: 4% | |
Spleen: 10–15% | CB: 50% | |
Subset ratios (TrB: FM B) | BM 1:0.6 | BM 1:2.1 |
PB 1:0.4 | PB 1:2.2 | |
Spleen 1:3.7 | Spleen 1:21.9 |